CMRX Stock Overview
Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Chimerix, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.89 |
| 52 Week High | US$1.57 |
| 52 Week Low | US$0.88 |
| Beta | 1.1 |
| 1 Month Change | -10.00% |
| 3 Month Change | -4.15% |
| 1 Year Change | -21.15% |
| 3 Year Change | -90.09% |
| 5 Year Change | -65.73% |
| Change since IPO | -95.26% |
Recent News & Updates
Recent updates
Chimerix: Advancement For Rare Brain Cancer Drug Targeting Specific Mutation
Aug 23Here's Why We're Watching Chimerix's (NASDAQ:CMRX) Cash Burn Situation
Jul 20
Chimerix: Down But Not Out
Jun 06Chimerix: Searching For Clarity
Jan 05Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?
Dec 24Is Chimerix (NASDAQ:CMRX) A Risky Investment?
Sep 16Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?
Jun 08Chimerix gets FDA approval for TEMBEXA for the treatment of smallpox
Jun 04Chimerix, Inc. (NASDAQ:CMRX): Are Analysts Optimistic?
May 13Chimerix Investor Presentation - Slideshow
May 08Chimerix expands oncology program with acquisition of Oncoceutics, shares up 10%
Jan 08Who Has Been Buying Chimerix, Inc. (NASDAQ:CMRX) Shares?
Jan 01
Chimerix rises 9.1% premarket after FDA accepts NDA for smallpox countermeasure
Dec 07Chimerix (NASDAQ:CMRX) Is In A Good Position To Deliver On Growth Plans
Dec 05Chimerix, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 08Chimerix EPS misses by $0.01, beats on revenue
Nov 05Shareholder Returns
| CMRX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.4% | 0.4% | 1.0% |
| 1Y | -21.2% | 0.9% | 21.9% |
Price Volatility
| CMRX volatility | |
|---|---|
| CMRX Average Weekly Movement | 8.4% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CMRX's share price has been volatile over the past 3 months.
Volatility Over Time: CMRX's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 72 | Mike Andriole | www.chimerix.com |
Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2.
Chimerix, Inc. Fundamentals Summary
| CMRX fundamental statistics | |
|---|---|
| Market cap | US$79.49m |
| Earnings (TTM) | -US$82.09m |
| Revenue (TTM) | US$324.00k |
245.3x
P/S Ratio-1.0x
P/E RatioIs CMRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CMRX income statement (TTM) | |
|---|---|
| Revenue | US$324.00k |
| Cost of Revenue | US$68.79m |
| Gross Profit | -US$68.46m |
| Other Expenses | US$13.63m |
| Earnings | -US$82.09m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 01, 2024
| Earnings per share (EPS) | -0.92 |
| Gross Margin | -21,130.86% |
| Net Profit Margin | -25,337.96% |
| Debt/Equity Ratio | 0% |
How did CMRX perform over the long term?
See historical performance and comparison